Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Assessing high-risk AML

Nigel Russell • 15 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia

Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, explores how high-risk acute myeloid leukemia (AML) can be identified as well as the importance of genomic profiling and minimal residual disease (MRD) in AML assessment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nigel Russell

1:02
AML19: FLAG-Ida vs CPX-351 in patients with AML with adverse risk cytogenetics
Nigel Russell • 10 Jun 2023
1:21
Gemtuzumab-based induction chemotherapy with midostaurin in FLT3-mutated AML
Nigel Russell • 10 Jun 2023
1:52
AML19 update: improvement in OS in patients with NPM1-mutated AML treated with FLAG-Ida-GO
Nigel Russell • 10 Jun 2023
3:26
AML19 trial: FLAG-Ida-GO vs DA-GO in standard-risk AML and FLAG-Ida vs CPX-351 in high-risk AML
Nigel Russell • 12 Dec 2022

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals